INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA

Translated title of the contribution: Pharmacological interactions between Lamotrigine and Carbamazepine or Phenytoin

P. G. Zagnoni, S. Giubergia, G. Zaccara, G. C. Muscas, A. Tartara, R. Manni, C. M. Cornaggia, S. Gianetti, S. Binelli, G. Avanzini

Research output: Contribution to journalArticle

Abstract

The modifications of the plasma concentrations of CBZ, PHT and LTG have been analyzed during a multicenter international study on the efficacy of LTG. 21 subjects were treated with PHT monotherapy and 19 with CBZ monotherapy and respectively 9 and 6 patients were dropped out of the study for protocol violations or interruption in an early phase. Only 12 patients treated with PHT and 13 patients treated with CBZ completed the study. Mean PHT concentration, at constant daily dose, was reduced from 18.2 μg/ml during PHT monotherapy to 13.8 μg/ml during PHT + LTG. A detailed analysis shows that 8 patients presented a reduction (median 45%, range 17-59%) while 4 patients presented an increase (median 23%, range 5-36%) of PHT plasma concentrations. Mean CBZ concentration, at constant daily dose, varied from 9.6 to 9.1 μg/ml during CBZ monotherapy and CBZ + LTG respectively, however a deeper analysis shows that 7 patients presented a reduction (median 18%, range 8-40) while 4 patients showed an increase (median 23%, range 6-42%) of CBZ plasma levels, which remained stable in 2 patients. During the passage from bitherapy LTG + PHT or LTG + CBZ to LTG monotherapy all the patients showed an increase of LTG plasma levels at constant LTG daily dose. PHT patients showed a mean LTG concentration of 2 μg/ml during add-on therapy, which raised to 5.9 μg/ml during LTG monotherapy with an increased average of 300%, range 209-890%. CBZ patients showed a mean LTG concentration of 2.2 μg/ml which raised to 4.6 μg/ml during LTG monotherapy with an increased average of 186%, range 130-430%. This trend was still present after 3 months of LTG monotherapy. The data show the existence of a drug interaction between LTG, CBZ and PHT and indicate the usefulness of therapeutic drug monitoring of all these AEDs.

Original languageItalian
Pages (from-to)131-134
Number of pages4
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number86-87
Publication statusPublished - 1994

Fingerprint

Carbamazepine
Phenytoin
Pharmacology
lamotrigine
Drug Monitoring
Drug Interactions
Multicenter Studies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Zagnoni, P. G., Giubergia, S., Zaccara, G., Muscas, G. C., Tartara, A., Manni, R., ... Avanzini, G. (1994). INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA. Bollettino - Lega Italiana contro l'Epilessia, (86-87), 131-134.

INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA. / Zagnoni, P. G.; Giubergia, S.; Zaccara, G.; Muscas, G. C.; Tartara, A.; Manni, R.; Cornaggia, C. M.; Gianetti, S.; Binelli, S.; Avanzini, G.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 86-87, 1994, p. 131-134.

Research output: Contribution to journalArticle

Zagnoni, PG, Giubergia, S, Zaccara, G, Muscas, GC, Tartara, A, Manni, R, Cornaggia, CM, Gianetti, S, Binelli, S & Avanzini, G 1994, 'INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA', Bollettino - Lega Italiana contro l'Epilessia, no. 86-87, pp. 131-134.
Zagnoni PG, Giubergia S, Zaccara G, Muscas GC, Tartara A, Manni R et al. INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA. Bollettino - Lega Italiana contro l'Epilessia. 1994;(86-87):131-134.
Zagnoni, P. G. ; Giubergia, S. ; Zaccara, G. ; Muscas, G. C. ; Tartara, A. ; Manni, R. ; Cornaggia, C. M. ; Gianetti, S. ; Binelli, S. ; Avanzini, G. / INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA. In: Bollettino - Lega Italiana contro l'Epilessia. 1994 ; No. 86-87. pp. 131-134.
@article{b9cea9d65f2b43999f1bebc63f98a351,
title = "INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA",
abstract = "The modifications of the plasma concentrations of CBZ, PHT and LTG have been analyzed during a multicenter international study on the efficacy of LTG. 21 subjects were treated with PHT monotherapy and 19 with CBZ monotherapy and respectively 9 and 6 patients were dropped out of the study for protocol violations or interruption in an early phase. Only 12 patients treated with PHT and 13 patients treated with CBZ completed the study. Mean PHT concentration, at constant daily dose, was reduced from 18.2 μg/ml during PHT monotherapy to 13.8 μg/ml during PHT + LTG. A detailed analysis shows that 8 patients presented a reduction (median 45{\%}, range 17-59{\%}) while 4 patients presented an increase (median 23{\%}, range 5-36{\%}) of PHT plasma concentrations. Mean CBZ concentration, at constant daily dose, varied from 9.6 to 9.1 μg/ml during CBZ monotherapy and CBZ + LTG respectively, however a deeper analysis shows that 7 patients presented a reduction (median 18{\%}, range 8-40) while 4 patients showed an increase (median 23{\%}, range 6-42{\%}) of CBZ plasma levels, which remained stable in 2 patients. During the passage from bitherapy LTG + PHT or LTG + CBZ to LTG monotherapy all the patients showed an increase of LTG plasma levels at constant LTG daily dose. PHT patients showed a mean LTG concentration of 2 μg/ml during add-on therapy, which raised to 5.9 μg/ml during LTG monotherapy with an increased average of 300{\%}, range 209-890{\%}. CBZ patients showed a mean LTG concentration of 2.2 μg/ml which raised to 4.6 μg/ml during LTG monotherapy with an increased average of 186{\%}, range 130-430{\%}. This trend was still present after 3 months of LTG monotherapy. The data show the existence of a drug interaction between LTG, CBZ and PHT and indicate the usefulness of therapeutic drug monitoring of all these AEDs.",
author = "Zagnoni, {P. G.} and S. Giubergia and G. Zaccara and Muscas, {G. C.} and A. Tartara and R. Manni and Cornaggia, {C. M.} and S. Gianetti and S. Binelli and G. Avanzini",
year = "1994",
language = "Italian",
pages = "131--134",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "86-87",

}

TY - JOUR

T1 - INTERAZIONI FARMACOLOGICHE DELLA LAMOTRIGINA CON CARBAMAZEPINA E FENITOINA

AU - Zagnoni, P. G.

AU - Giubergia, S.

AU - Zaccara, G.

AU - Muscas, G. C.

AU - Tartara, A.

AU - Manni, R.

AU - Cornaggia, C. M.

AU - Gianetti, S.

AU - Binelli, S.

AU - Avanzini, G.

PY - 1994

Y1 - 1994

N2 - The modifications of the plasma concentrations of CBZ, PHT and LTG have been analyzed during a multicenter international study on the efficacy of LTG. 21 subjects were treated with PHT monotherapy and 19 with CBZ monotherapy and respectively 9 and 6 patients were dropped out of the study for protocol violations or interruption in an early phase. Only 12 patients treated with PHT and 13 patients treated with CBZ completed the study. Mean PHT concentration, at constant daily dose, was reduced from 18.2 μg/ml during PHT monotherapy to 13.8 μg/ml during PHT + LTG. A detailed analysis shows that 8 patients presented a reduction (median 45%, range 17-59%) while 4 patients presented an increase (median 23%, range 5-36%) of PHT plasma concentrations. Mean CBZ concentration, at constant daily dose, varied from 9.6 to 9.1 μg/ml during CBZ monotherapy and CBZ + LTG respectively, however a deeper analysis shows that 7 patients presented a reduction (median 18%, range 8-40) while 4 patients showed an increase (median 23%, range 6-42%) of CBZ plasma levels, which remained stable in 2 patients. During the passage from bitherapy LTG + PHT or LTG + CBZ to LTG monotherapy all the patients showed an increase of LTG plasma levels at constant LTG daily dose. PHT patients showed a mean LTG concentration of 2 μg/ml during add-on therapy, which raised to 5.9 μg/ml during LTG monotherapy with an increased average of 300%, range 209-890%. CBZ patients showed a mean LTG concentration of 2.2 μg/ml which raised to 4.6 μg/ml during LTG monotherapy with an increased average of 186%, range 130-430%. This trend was still present after 3 months of LTG monotherapy. The data show the existence of a drug interaction between LTG, CBZ and PHT and indicate the usefulness of therapeutic drug monitoring of all these AEDs.

AB - The modifications of the plasma concentrations of CBZ, PHT and LTG have been analyzed during a multicenter international study on the efficacy of LTG. 21 subjects were treated with PHT monotherapy and 19 with CBZ monotherapy and respectively 9 and 6 patients were dropped out of the study for protocol violations or interruption in an early phase. Only 12 patients treated with PHT and 13 patients treated with CBZ completed the study. Mean PHT concentration, at constant daily dose, was reduced from 18.2 μg/ml during PHT monotherapy to 13.8 μg/ml during PHT + LTG. A detailed analysis shows that 8 patients presented a reduction (median 45%, range 17-59%) while 4 patients presented an increase (median 23%, range 5-36%) of PHT plasma concentrations. Mean CBZ concentration, at constant daily dose, varied from 9.6 to 9.1 μg/ml during CBZ monotherapy and CBZ + LTG respectively, however a deeper analysis shows that 7 patients presented a reduction (median 18%, range 8-40) while 4 patients showed an increase (median 23%, range 6-42%) of CBZ plasma levels, which remained stable in 2 patients. During the passage from bitherapy LTG + PHT or LTG + CBZ to LTG monotherapy all the patients showed an increase of LTG plasma levels at constant LTG daily dose. PHT patients showed a mean LTG concentration of 2 μg/ml during add-on therapy, which raised to 5.9 μg/ml during LTG monotherapy with an increased average of 300%, range 209-890%. CBZ patients showed a mean LTG concentration of 2.2 μg/ml which raised to 4.6 μg/ml during LTG monotherapy with an increased average of 186%, range 130-430%. This trend was still present after 3 months of LTG monotherapy. The data show the existence of a drug interaction between LTG, CBZ and PHT and indicate the usefulness of therapeutic drug monitoring of all these AEDs.

UR - http://www.scopus.com/inward/record.url?scp=0028674519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028674519&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0028674519

SP - 131

EP - 134

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 86-87

ER -